罕见高白细胞 T 淋巴母细胞淋巴瘤/白血病伴 <i>PICALM-MLLT10</i> 融合、多基因突变一例_West China Medical Journal

Authors：

刘彦权 ¹ , 沈建箴 ¹ , 张浪辉 ¹ , 付海英 ¹ , 陈伟鸿 ² , 谢水玲 ³ , MohammedAwal Issah ¹ ,  周华蓉 ¹

1. ;
2. ;
3. ;

Corresponding author：

周华蓉, Email: zhouhuarong2002@aliyun.com

Keywords：

T 淋巴母细胞淋巴瘤/白血病; 高白细胞; PICALM-MLLT10 融合; 多基因突变; 预后

DOI：

10.7507/1002-0179.201908071

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 刘彦权, 沈建箴, 张浪辉, 付海英, 陈伟鸿, 谢水玲, MohammedAwal Issah, 周华蓉. 罕见高白细胞 T 淋巴母细胞淋巴瘤/白血病伴 PICALM-MLLT10 融合、多基因突变一例. West China Medical Journal, 2019, 34(12): 1446-1449. doi: 10.7507/1002-0179.201908071 Copy

1.	Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues//WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer Press, 2008: 176-178.
2.	张艳华, 李静, 郗彦凤. T 淋巴母细胞白血病/淋巴瘤分子遗传学研究进展. 白血病·淋巴瘤, 2016, 25(6): 381-384.
3.	关伟, 靖彧, 于力. 分子遗传学和表观遗传学异常在 T 淋巴母细胞淋巴瘤/白血病中的预后价值的研究进展. 中国实验血液学杂志, 2017, 25(2): 587-591.
4.	赵双平, 赵银利, 王景昌. 11 例高白细胞急性白血病死亡病例分析. 临床医学研究与实践, 2019, 4(5): 150-151.
5.	Nguyen R, Jeha S, Zhou Y, et al. The role of leukapheresis in the current management of hyperleukocytosis in newly diagnosed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer, 2016, 63(9): 1546-1551.
6.	Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J, 2017, 7(6): e577.
7.	Kong SG, Seo JH, Jun SE, et al. Childhood acute lymphoblastic leukemia with hyperleukocytosis at presentation. Blood Res, 2014, 49(1): 29-35.
8.	Giammarco S, Chiusolo P, Piccirillo N, et al. Hyperleukocytosis and leukostasis: management of a medical emergency. Expert Rev Hematol, 2017, 10(2): 147-154.
9.	Brandwein JM, Zhu N, Kumar R, et al. Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines. Am J Blood Res, 2017, 7(4): 30-40.
10.	Chen B, Yan X, Zhang X, et al. Leukostasis retinopathy: an uncommon visual threatening complication of chronic myeloid leukemia with severe hyperleukocytosis - a case report and review of the literature. Indian J Ophthalmol, 2018, 66(12): 1871-1874.
11.	van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia, 2003, 17(12): 2257-2317.
12.	童春容, 王卉, 林跃辉, 等. 9 例γδT细胞淋巴瘤/白血病患者的临床及实验室特征. 中华血液学杂志, 2011, 32(7): 445-449.
13.	Borel C, Dastugue N, Cances-Lauwers V, et al. PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients. Leuk Res, 2012, 36(11): 1365-1369.
14.	Ben Abdelali R, Asnafi V, Petit A, et al. The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. Haematologica, 2013, 98(11): 1711-1717.
15.	Stein EM, Garcia-Manero G, Rizzieri DA, et al. The DOT1L inhibitor EPZ-5676: safety and activity in relapsed/refractory patients with MLL-rearranged leukemia. Blood, 2014, 124: 387.
16.	Bordin F, Piovan E, Masiero E, et al. WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia. Haematologica, 2018, 103(2): 266-277.
17.	Stief SM, Hanneforth AL, Weser S, et al. Loss of KDM6A confers drug resistance in acute myeloid leukemia. Leukemia, 2019.
18.	Li M, Xiao L, Xu J, et al. Co-existence of PHF6 and NOTCH1 mutations in adult T-cell acute lymphoblastic leukemia. Oncol Lett, 2016, 12(1): 16-22.
19.	Gu Y, Han Q, McGrath M, et al. Clinical significance of novel SH2B3 mutations in adult Chinese acute lymphoblastic leukemia patients. Leuk Res, 2018, 72: 67-70.
20.	Jenkins CE, Gusscott S, Wong RJ, et al. RUNX1 promotes cell growth in human T-cell acute lymphoblastic leukemia by transcriptional regulation of key target genes. Exp Hematol, 2018, 64: 84-96.
21.	张弦, 张改玲, 苏云超, 等. 西达本胺联合化疗治疗复发难治性急性白血病患者 38 例. 中国新药与临床杂志, 2019, 38(6): 357-362.
22.	Zelenetz AD, Wierda WG, Abramson JS, et al. Non-Hodgkin’s Lymphomas, version 3.2012. J Natl Compr Canc Netw, 2012, 10(12): 1487-1498.

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues//WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer Press, 2008: 176-178.
2. 张艳华, 李静, 郗彦凤. T 淋巴母细胞白血病/淋巴瘤分子遗传学研究进展. 白血病·淋巴瘤, 2016, 25(6): 381-384.
3. 关伟, 靖彧, 于力. 分子遗传学和表观遗传学异常在 T 淋巴母细胞淋巴瘤/白血病中的预后价值的研究进展. 中国实验血液学杂志, 2017, 25(2): 587-591.
4. 赵双平, 赵银利, 王景昌. 11 例高白细胞急性白血病死亡病例分析. 临床医学研究与实践, 2019, 4(5): 150-151.
5. Nguyen R, Jeha S, Zhou Y, et al. The role of leukapheresis in the current management of hyperleukocytosis in newly diagnosed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer, 2016, 63(9): 1546-1551.
6. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J, 2017, 7(6): e577.
7. Kong SG, Seo JH, Jun SE, et al. Childhood acute lymphoblastic leukemia with hyperleukocytosis at presentation. Blood Res, 2014, 49(1): 29-35.
8. Giammarco S, Chiusolo P, Piccirillo N, et al. Hyperleukocytosis and leukostasis: management of a medical emergency. Expert Rev Hematol, 2017, 10(2): 147-154.
9. Brandwein JM, Zhu N, Kumar R, et al. Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines. Am J Blood Res, 2017, 7(4): 30-40.
10. Chen B, Yan X, Zhang X, et al. Leukostasis retinopathy: an uncommon visual threatening complication of chronic myeloid leukemia with severe hyperleukocytosis - a case report and review of the literature. Indian J Ophthalmol, 2018, 66(12): 1871-1874.
11. van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 concerted action BMH4-CT98-3936. Leukemia, 2003, 17(12): 2257-2317.
12. 童春容, 王卉, 林跃辉, 等. 9 例γδT细胞淋巴瘤/白血病患者的临床及实验室特征. 中华血液学杂志, 2011, 32(7): 445-449.
13. Borel C, Dastugue N, Cances-Lauwers V, et al. PICALM-MLLT10 acute myeloid leukemia: a French cohort of 18 patients. Leuk Res, 2012, 36(11): 1365-1369.
14. Ben Abdelali R, Asnafi V, Petit A, et al. The prognosis of CALM-AF10-positive adult T-cell acute lymphoblastic leukemias depends on the stage of maturation arrest. Haematologica, 2013, 98(11): 1711-1717.
15. Stein EM, Garcia-Manero G, Rizzieri DA, et al. The DOT1L inhibitor EPZ-5676: safety and activity in relapsed/refractory patients with MLL-rearranged leukemia. Blood, 2014, 124: 387.
16. Bordin F, Piovan E, Masiero E, et al. WT1 loss attenuates the TP53-induced DNA damage response in T-cell acute lymphoblastic leukemia. Haematologica, 2018, 103(2): 266-277.
17. Stief SM, Hanneforth AL, Weser S, et al. Loss of KDM6A confers drug resistance in acute myeloid leukemia. Leukemia, 2019.
18. Li M, Xiao L, Xu J, et al. Co-existence of PHF6 and NOTCH1 mutations in adult T-cell acute lymphoblastic leukemia. Oncol Lett, 2016, 12(1): 16-22.
19. Gu Y, Han Q, McGrath M, et al. Clinical significance of novel SH2B3 mutations in adult Chinese acute lymphoblastic leukemia patients. Leuk Res, 2018, 72: 67-70.
20. Jenkins CE, Gusscott S, Wong RJ, et al. RUNX1 promotes cell growth in human T-cell acute lymphoblastic leukemia by transcriptional regulation of key target genes. Exp Hematol, 2018, 64: 84-96.
21. 张弦, 张改玲, 苏云超, 等. 西达本胺联合化疗治疗复发难治性急性白血病患者 38 例. 中国新药与临床杂志, 2019, 38(6): 357-362.
22. Zelenetz AD, Wierda WG, Abramson JS, et al. Non-Hodgkin’s Lymphomas, version 3.2012. J Natl Compr Canc Netw, 2012, 10(12): 1487-1498.

Previous Article
Progress on the role of nuclear factor-erythroid 2-related factor 2 in regulating cell proliferation
Next Article
超声乳化白内障术后恶性青光眼一例

West China Medical Journal

罕见高白细胞 T 淋巴母细胞淋巴瘤/白血病伴 PICALM-MLLT10 融合、多基因突变一例

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content